Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SENP5 | Q96HI0 | 15/20 | 0.49 |
| ▸ | SENP2 | Q9HC62 | 15/20 | 0.49 |
| ▸ | SENP1 | Q9P0U3 | 15/20 | 0.49 |
| ▸ | MPO | P05164 | 1/20 | 0.49 |
| ▸ | CYSLTR1 | Q9Y271 | 1/20 | 0.49 |
| ▸ | EDNRA | P25101 | 1/20 | 0.48 |
| ▸ | SCD | O00767 | 1/20 | 0.45 |
| ▸ | USP2 | O75604 | 1/20 | 0.45 |
| ▸ | ICAM1 | P05362 | 1/20 | 0.43 |
| ▸ | SELE | P16581 | 1/20 | 0.43 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9374999 | 0.93 | SENP5 (0.53) | SENP5SENP2SENP1SCDUSP2 | |
| SCHEMBL9377138 | 0.89 | SENP5 (0.47) | SENP5SENP2SENP1USP2 | |
| SCHEMBL9371073 | 0.89 | EDNRA (0.66) | SENP5SENP2SENP1MPOCYSLTR1 | |
| SCHEMBL6568247 | 0.88 | MPO (0.51) | SENP5SENP2SENP1MPOCYSLTR1 | |
| SCHEMBL10372978 | 0.88 | MPO (0.52) | SENP5SENP2SENP1MPOCYSLTR1 | |
| SCHEMBL9247114 | 0.87 | MPO (0.56) | SENP5SENP2SENP1MPOCYSLTR1 | |
| SCHEMBL6812831 | 0.83 | POLB (0.42) | MPOCYSLTR1 | |
| SCHEMBL10371017 | 0.83 | MPO (0.52) | MPOCYSLTR1SCDICAM1SELE | |
| SCHEMBL6440669 | 0.83 | MPO (0.69) | MPOCYSLTR1EDNRAICAM1SELE | |
| SCHEMBL8767124 | 0.82 | MPO (0.68) | MPOCYSLTR1EDNRAICAM1SELE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6471997-B1 | ANTAGONIST OF CALCITONIN GENE RELATED PEPTIDE, CGRP AND/OR OF SUBSTANCE P; COSMETIC | SOCIETE L'OREAL S.A. (FR) | 2002-10-29 | — | — | US | claimed |
| US-5993833-A | Histamine antagonist, an interleukin-1 antagonist and/or a TNF alpha antagonist in a cosmetic, pharmaceutical or dermatological composition | SOCIETE L'OREAL S.A. (FR) | 1999-11-30 | — | — | US | claimed |
| EP-0765668-B1 | Extract of Iridaceas and compositions containing it | OREAL (FR) | 1999-03-17 | — | — | EP | claimed |
| US-5795574-A | COSMETICS WITH SUBSTANCE P ANTAGONIST | SOCIETE L'OREAL S.A. (FR) | 1998-08-18 | — | — | US | claimed |
| EP-0761204-B1 | Use of extracts of filamentous, non photosynthetic bacteria and the composition containing them | OREAL (FR) | 1998-04-15 | — | — | EP | claimed |
| EP-0765668-A1 | Extract of Iridaceas and composition containing it | L'OREAL (FR) | 1997-04-02 | — | — | EP | claimed |
| WO-1997009032-A1 | UTILIZATION OF AN EXTRACT OF A NON PHOTOSYNTHETIC FILAMENTARY BACTERIUM AND COMPOSITION CONTAINING SUCH EXTRACT | L'OREAL (FR) | 1997-03-13 | — | — | WO | claimed |
| WO-1997009056-A1 | EXTRACT OF IRIDACEAE AND COMPOSITIONS CONTAINING SUCH EXTRACT | L'OREAL (FR) | 1997-03-13 | — | — | WO | claimed |
| EP-0761204-A1 | Use of extracts of filamentous, non photosynthetic bacteria and the composition containing them | L'OREAL (FR) | 1997-03-12 | — | — | EP | claimed |
| EP-0299457-B1 | Novel benzothiophenes having antiallergic activity and both novel and other selected benzothiophenes having activity for treating acute respiratory distress syndrome | WARNER LAMBERT CO (US) | 1994-09-21 | — | — | EP | claimed |
| US-4931459-A | ADMINISTERING SUBSTITUTED BENZOTHIOPHENES OR BENZOFURANS | WARNER-LAMBERT COMPANY (US) | 1990-06-05 | — | — | US | claimed |
| EP-1491183-A2 | Use of a plant extract of the Rosaceae family | L'OREAL (FR) | 2004-12-29 | — | — | EP | disclosed |
| EP-0729750-B1 | Alpha-TNF antagonists in a cosmetic, pharmaceutical or dermatological composition. | OREAL (FR) | 2004-03-24 | — | — | EP | disclosed |
| US-20010022978-A1 | Cosmetic, pharmaceutical or dermatological composition comprising a histamine antagonist, an interleukin-1 antagonist and/or a TNF-alpha antagonist | LACHARRIERE OLIVIER DE (FR) | 2001-09-20 | — | — | US | disclosed |
| US-6277387-B1 | Use of a histamine antagonist, an interleukin-1 antagonist and/or a TNF αantagonist in a cosmetic, pharmaceutical or dermatological composition and composition obtained | L'OREAL (FR) | 2001-08-21 | — | — | US | disclosed |
| EP-0761204-A1 | Use of extracts of filamentous, non photosynthetic bacteria and the composition containing them | L'OREAL (FR) | 1997-03-12 | — | — | EP | disclosed |
| EP-0729750-A1 | Use of an interleukin-1 antagonist and/or alpha-TNF antagonist in a cosmetic, pharmaceutical or dermatological composition, and the composition therefrom, possibly used in combination with a histamine antagonist | L'OREAL (FR) | 1996-09-04 | — | — | EP | disclosed |
| US-4931459-A | ADMINISTERING SUBSTITUTED BENZOTHIOPHENES OR BENZOFURANS | WARNER-LAMBERT COMPANY (US) | 1990-06-05 | — | — | US | disclosed |
| US-4910317-A | Containing a 5-amidetetrazole substitution in position 2 | WARNER-LAMBERT COMPANY (US) | 1990-03-20 | — | — | US | disclosed |
| EP-0299457-A2 | Novel benzothiophenes having antiallergic activity and both novel and other selected benzothiophenes having activity for treating acute respiratory distress syndrome | WARNER-LAMBERT COMPANY (US) | 1989-01-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010022978-A1 | Cosmetic, pharmaceutical or dermatological composition comprising a histamine antagonist, an interleukin-1 antagonist and/or a TNF-alpha antagonist | TNF, IL1A, IL1B | SENP5 1838/4885SENP2 1804/4885SENP1 853/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.